Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on August 6, 2026. The filing announces financial results and a business update for the quarter ended June 30, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. The document serves as a notification that results for the quarter ended June 30, 2026, have been issued.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are referenced as being part of the press release (Exhibit 99.1) but are not detailed in the body of this Form 8-K. The filing explicitly states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 financial figures.
- Verify the company's cash position and burn rate in the full press release.
- Check for any updates on clinical trial progress or commercial partnerships mentioned in the business update.
- Confirm if the company provided updated full-year 2026 guidance in the referenced press release.